[{"address1": "The SchrOedinger Building", "address2": "Oxford Science Park", "city": "Oxford", "zip": "OX4 4GE", "country": "United Kingdom", "phone": "44 18 6581 8941", "website": "https://www.exscientia.ai", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charit\u00e9 \u0096 Universit\u00e4tsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.", "fullTimeEmployees": 483, "companyOfficers": [{"maxAge": 1, "name": "Dr. David  Hallett Ph.D.", "age": 54, "title": "Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben R. Taylor", "age": 46, "title": "CFO, Chief Strategy Officer & Executive Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 558080, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Overington Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sara  Sherman", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Ireland", "title": "Executive VP of Legal & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Parker  Moss", "title": "Executive Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Rowland", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Law", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nikolaus  Krall", "title": "Executive Vice President of Precision Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.", "age": 59, "title": "Interim Chief Medical Officer & Clinical Development Lead", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.84, "open": 4.6, "dayLow": 4.84, "dayHigh": 4.84, "regularMarketPreviousClose": 4.84, "regularMarketOpen": 4.6, "regularMarketDayLow": 4.84, "regularMarketDayHigh": 4.84, "beta": 0.835, "forwardPE": -8.451196, "volume": 1454597, "regularMarketVolume": 1454597, "averageVolume": 693495, "averageVolume10days": 1171634, "averageDailyVolume10Day": 1171634, "marketCap": 633178496, "fiftyTwoWeekLow": 3.8, "fiftyTwoWeekHigh": 7.91, "priceToSalesTrailing12Months": 37.09523, "fiftyDayAverage": 5.0389, "twoHundredDayAverage": 5.264625, "currency": "USD", "enterpriseValue": 407419040, "floatShares": 84167396, "sharesOutstanding": 130822000, "sharesShort": 2811413, "sharesShortPriorMonth": 2887920, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0215, "heldPercentInsiders": 0.25902998, "heldPercentInstitutions": 0.20805, "shortRatio": 5.77, "shortPercentOfFloat": 0.043, "impliedSharesOutstanding": 130822000, "bookValue": 1.953, "priceToBook": 2.4782388, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -150512992, "trailingEps": -1.51, "forwardEps": -0.83, "enterpriseToRevenue": 23.869, "enterpriseToEbitda": -2.741, "52WeekChange": -0.23538703, "SandP52WeekChange": 0.25891924, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "EXAI", "underlyingSymbol": "EXAI", "shortName": "Exscientia Plc", "longName": "Exscientia plc", "firstTradeDateEpochUtc": 1633095000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "338b7c25-91d3-36d5-9c38-0f21999063b2", "messageBoardId": "finmb_408328234", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.84, "targetHighPrice": 4.353, "targetLowPrice": 4.353, "targetMeanPrice": 4.353, "targetMedianPrice": 4.353, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 244076000, "totalCashPerShare": 1.866, "ebitda": -148656000, "totalDebt": 18569000, "quickRatio": 4.454, "currentRatio": 4.537, "totalRevenue": 17069000, "debtToEquity": 7.27, "revenuePerShare": 0.135, "returnOnAssets": -0.21215001, "returnOnEquity": -0.46427, "freeCashflow": -71966752, "operatingCashflow": -102620000, "revenueGrowth": -0.445, "grossMargins": -0.67737, "operatingMargins": -10.66024, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]